An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland

An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland

Richard F Pollock,1 Lisa M Meckley2 1Ossian Health Economics and Communications GmbH, Health Economics and Outcomes Research, Basel, Switzerland; 2Shire Plc, Outcomes Research and Epidemiology, Cambridge, MA, USA Introduction: While most individual primary immunodeficiency diseases (PID) are rare, t...

Full description

Bibliographic Details
Main Authors: Pollock RF, Meckley LM
Format: Article
Language:English
Published: Dove Medical Press 2018-04-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
Costs and Cost Analysis
Immune System Diseases
Immunoglobulin
Switzerland
Online Access:https://www.dovepress.com/an-evaluation-of-the-budget-impact-of-a-new-20-subcutaneous-immunoglob-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/an-evaluation-of-the-budget-impact-of-a-new-20-subcutaneous-immunoglob-peer-reviewed-article-CEOR

Similar Items